Resource‐appropriate selection of osteosarcoma treatment protocols in low‐ and middle‐income countries

Osteosarcoma is a rare malignancy; however, it is still the most common primary bone tumor in adolescents and young adults. Chemotherapy improves survival indubitably in osteosarcoma; nevertheless, the concern is the stagnant progress since the last several decades. There are a handful of active age...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2022-03, Vol.69 (3), p.e29540-n/a
Main Authors: Mailankody, Sharada, Kumar, Venkatesan Sampath, Khan, Shah Alam, Banavali, Shripad D., Bajpai, Jyoti
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone cancer
Bone Neoplasms - pathology
Bone tumors
Chemotherapy
current management strategies
Decision making
Developing Countries
Hematology
Humans
low‐ and middle‐income countries
Malignancy
Methotrexate
Methotrexate - therapeutic use
non‐high‐dose methotrexate protocols
Oncology
Osteosarcoma
Osteosarcoma - drug therapy
Pediatrics
practical considerations
Sarcoma
Young Adult
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma is a rare malignancy; however, it is still the most common primary bone tumor in adolescents and young adults. Chemotherapy improves survival indubitably in osteosarcoma; nevertheless, the concern is the stagnant progress since the last several decades. There are a handful of active agents and unresolved issues, especially in choosing the ideal chemotherapy regimen. The oncology community is in equipoise regarding the position of high‐dose methotrexate (HDMTX), mandatory or adjunct. The choice of therapy becomes widely relevant, including in low‐ and middle‐income countries (LMIC), where HDMTX administration brings additional complexities. Research into novel non‐HDMTX‐based protocols adapted to the available resources is pivotal in improving disease outcomes, especially in LMIC. The current review focuses on real‐world challenges in decision‐making and provides a comprehensive overview of the evolution of treatment protocols in LMIC.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29540